Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity by Bol, K.F. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/171284
 
 
 
Please be advised that this information was generated on 2019-06-01 and may be subject to
change.
1 3
Cancer Immunol Immunother (2016) 65:327–339
DOI 10.1007/s00262-016-1796-7
ORIGINAL ARTICLE
Prophylactic vaccines are potent activators of monocyte‑derived 
dendritic cells and drive effective anti‑tumor responses 
in melanoma patients at the cost of toxicity
Kalijn F. Bol1,2 · Erik H. J. G. Aarntzen1,2,5 · Jeanette M. Pots1 · Michel A. M. Olde Nordkamp1 · 
Mandy W. M. M. van de Rakt1 · Nicole M. Scharenborg1 · Annemiek J. de Boer1 · Tom G. M. van Oorschot1 · 
Sandra A. J. Croockewit3 · Willeke A. M. Blokx4 · Wim J. G. Oyen5 · Otto C. Boerman5 · Roel D. M. Mus5 · 
Michelle M. van Rossum6 · Chantal A. A. van der Graaf7 · Cornelis J. A. Punt8 · Gosse J. Adema1 · Carl G. Figdor1 · 
I. Jolanda M. de Vries1,2 · Gerty Schreibelt1 
Received: 24 September 2015 / Accepted: 11 January 2016 / Published online: 10 February 2016 
© The Author(s) 2016. This article is published with open access at Springerlink.com
(KLH) and mRNA encoding tumor antigens gp100 and 
tyrosinase. Tumor antigen-specific T cell responses were 
monitored in blood and skin-test infiltrating-lymphocyte 
cultures. Almost all patients mounted prophylactic vaccine- 
or KLH-specific immune responses. Both after intranodal 
injection and after intradermal/intravenous injection, tumor 
antigen-specific immune responses were detected, which 
coincide with longer overall survival in stage IV melanoma 
patients. VAC-DC induce local and systemic CTC grade 2 
and 3 toxicity, which is most likely caused by BCG in the 
maturation cocktail. The side effects were self-limiting or 
resolved upon a short period of systemic steroid therapy. 
We conclude that VAC-DC can induce functional tumor-
specific responses. Unfortunately, toxicity observed after 
vaccination precludes the general application of VAC-DC, 
since in DC maturated with prophylactic vaccines BCG 
appears to be essential in the maturation cocktail.
Keywords Dendritic cells · Immunotherapy · Melanoma · 
Toll-like receptor ligands · Maturation · Prophylactic 
vaccines
Abbreviations
BAL  Bronchoalveolar lavage
cDC  Cytokine-matured DC
DC  Dendritic cell(s)
DTH  Delayed-type hypersensitivity
GMP  Good manufacturing practice
i.d.  Intradermal
IFNγ  Interferon gamma
i.n.  Intranodal
i.v.  Intravenous
KLH  Keyhole limpet hemocyanin
moDC  Monocyte-derived DC
PBMC  Peripheral blood mononuclear cells
Abstract Dendritic cell (DC)-based immunotherapy is 
explored worldwide in cancer patients, predominantly with 
DC matured with pro-inflammatory cytokines and prosta-
glandin E2. We studied the safety and efficacy of vaccina-
tion with monocyte-derived DC matured with a cocktail of 
prophylactic vaccines that contain clinical-grade Toll-like 
receptor ligands (BCG, Typhim, Act-HIB) and prostaglan-
din E2 (VAC-DC). Stage III and IV melanoma patients 
were vaccinated via intranodal injection (12 patients) or 
combined intradermal/intravenous injection (16 patients) 
with VAC-DC loaded with keyhole limpet hemocyanin 
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PGE2  Prostaglandin E2
SKIL  Skin-test infiltrating-lymphocytes
TAA  Tumor-associated antigen(s)
Th1  T helper 1
TLR  Toll-like receptor(s)
TNFα  Tumor necrosis factor alpha
VAC-DC  DC matured with prophylactic vaccines and 
PGE2
Introduction
Dendritic cells (DC) have the unique capacity to activate 
naive tumor-specific T cells [1]. They play a critical role 
in determining the magnitude and quality of the immune 
response to an antigen. Immunotherapy applying ex vivo-
generated and tumor antigen-loaded DC has now been 
introduced in the clinic [2, 3]. A limited, but consistent, 
number of objective immunological and clinical responses 
have been observed [3]. Thus far, it remains unclear why 
some patients respond while others do not, but there is a 
general consensus that the current protocols applied to gen-
erate DC may not result in the induction of optimal T helper 
1 (Th1) responses and hence cytotoxic T cell responses. 
We and others have demonstrated that DC maturation is 
one of the crucial factors to induce effective anti-tumor 
immune responses in cancer patients [4–7]. Currently, DC 
are mostly matured with a cocktail of pro-inflammatory 
cytokines, including IL-1β, IL-6, tumor necrosis factor 
alpha (TNFα), and prostaglandin E2 (PGE2). However, DC 
matured in the presence of Toll-like receptor (TLR) ligands 
may unleash more potent immune responses, as mouse 
studies have shown that TLR-matured DC are able to pro-
mote T helper 1 cell differentiation and induce full effec-
tor T cell differentiation [8]. TLR-mediated maturation of 
ex vivo-generated human monocyte-derived DC (moDC) 
may thus be used to improve immunological and clinical 
responses in DC vaccination of cancer patients.
TLR are pattern recognition receptors that sense micro-
bial and viral products, like bacterial cell wall components 
or double-stranded RNA. TLR engagement on DC induces 
maturation and cytokine secretion. In humans, 11 TLR have 
been described for which many specific ligands have been 
identified [9, 10]. Whereas several TLR ligands have been 
shown to yield mature Th1-directing DC, limited avail-
ability of Good Manufacturing Practice (GMP)-compliant 
produced ligands impede the use of these TLR ligands for 
the generation of DC for immunotherapy in patients. How-
ever, prophylactic vaccines against infectious diseases fre-
quently contain molecules derived from bacteria or viruses, 
which are natural TLR ligands. We identified a cocktail of 
the clinical-grade prophylactic vaccines BCG, Influvac, and 
Typhim that contains a multitude of natural TLR ligands 
and is capable of optimally maturing DC [11]. These so-
called prophylactic vaccine-matured DC showed high 
expression of CD80, CD83, and CD86 and secreted high 
levels of IL-12. Although these DC exhibited an impaired 
migratory capacity, this could be restored by addition of 
PGE2. DC matured with prophylactic vaccines and PGE2 
are potent inducers of T cell proliferation, Th1 polarization, 
and tumor antigen-specific CD8+ effector T cells ex vivo. 
Prophylactic vaccine-induced DC maturation is compatible 
with mRNA electroporation as an antigen loading strategy 
of DC [11]. Here, we studied the safety, immunoreactivity, 
migratory capacity, and efficacy of intravenous/intradermal 
(i.v./i.d.) or intranodal (i.n.) vaccination with DC matured 
with a prophylactic vaccine cocktail, consisting of the clin-
ical-grade prophylactic vaccines BCG, Typhim, and Act-
HIB, together with PGE2 (VAC-DC) in a dose escalation 
study in stage III and IV melanoma patients.
Patients and methods
Patient population
Melanoma patients with regional lymph node-positive 
resectable disease (further referred to as stage III), before 
or within 2 months after radical lymph node dissection, and 
patients with locally irresectable or distant metastatic dis-
ease (further referred to as stage IV) were included. Addi-
tional inclusion criteria were melanoma expressing gp100 
(compulsory) and tyrosinase (non-compulsory), and WHO 
performance status 0 or 1. In protocol A HLA-A*02:01 
phenotype was an additional inclusion criteria. Patients 
with brain metastases, serious concomitant disease, use of 
immunosuppressive drugs, or a history of a second malig-
nancy were excluded. The studies were approved by the 
Dutch Central Committee on Research involving Human 
Subjects, written informed consent was obtained from all 
patients, and all procedures were performed in accord-
ance with the Declaration of Helsinki. ClinicalTrials.gov 
registration numbers are NCT00940004 (protocol A) and 
NCT01530698 (protocol B).
Clinical protocol and immunization schedule
A leukapheresis was performed from which DC were gen-
erated. Patients received a VAC-DC vaccine i.v./i.d. (proto-
col A; 2/3 i.v. and 1/3 i.d.) or i.n. (protocol B; Supplemen-
tary Figure 1). Intranodal vaccination was conducted in a 
clinically tumor-free lymph node under ultrasound guid-
ance. The VAC-DC vaccine consisted of autologous mature 
moDC electroporated with mRNA coding for gp100 and 
tyrosinase protein, and pulsed with keyhole limpet hemo-
cyanin (KLH) protein. Patients received three biweekly 
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vaccinations per cycle. Eight patients received an extra 
vaccination before radical lymph node dissection for addi-
tional imaging studies. One to two weeks after the last vac-
cination, a skin test was performed. In absence of disease 
recurrence or progression, patients received a maximum 
of two maintenance cycles at 6-month intervals. All vac-
cinations were administered between June 2009 and May 
2012. Endpoints of this trial were safety, the induction of 
tumor antigen-specific immune responses, and the clinical 
response of stage IV patients according to the RECIST1.1 
criteria. Toxicity was assessed according to NCI CTC ver-
sion 3.0.
DC preparation and characterization
Monocytes were enriched from leukapheresis products by 
counterflow elutriation using Elutra cell separator (Gambro 
BCT) and cultured as described [5, 12]. In our preclinical 
study, we developed a TLR maturation cocktail consist-
ing of BCG, Typhim, and Influvac as clinical-grade alter-
native for synthetically produced TLR ligands for moDC 
maturation [11]. Since Influvac is only available during 
the flu season and has a different composition each year, 
we replaced Influvac by Act-HIB in our maturation cock-
tail. Both maturation cocktails gave rise to highly mature, 
IL-12-producing DC (Supplementary Figure 2). There-
fore, in the present study, DC were matured with a cock-
tail of prophylactic vaccines including BCG vaccine SSI 
(4 % v/v, Nederlands Vaccin Instituut), Typhim Vi (4 % 
v/v, Sanofi Pasteur MSD), and Act-HIB (4 % v/v, Aventis 
Pasteur), supplemented with PGE2 (10 µg/ml, Pharmacia 
and Upjohn) for 48 h (VAC-DC) [11]. For the delayed-type 
hypersensitivity (DTH) skin test, DC were matured either 
with the prophylactic vaccine cocktail or with a cytokine 
cocktail consisting of TNFα (10 ng/ml), IL-1β (5 ng/ml), 
IL-6 (15 ng/ml) (all CellGenix) and PGE2 (10 µg/ml) for 
48 h (cDC) [5]. Mature DC were electroporated with GMP-
grade gp100 and tyrosinase-encoding mRNA and charac-
terized by flow cytometry as described [13]. The release 
criteria were: ≥70 % viability, ≥50 % expression of CD83, 
and expression of MHC class I, MHC class II, CD80, 
CD86, and CCR7.
[111Indium] labeling and scintigraphy
DC migration was measured after the first vaccination by 
scintigraphic imaging as described [14]. DC were incu-
bated with 111In-oxine (GE Healthcare) in 0.1 ml/l Tris–
HCl (pH 7.0) for 15 min at room temperature. Cells were 
washed three times with PBS, 1 % HSA. In vivo planar 
scintigraphic images were acquired with a gamma-camera 
equipped with medium energy collimators, 10 min and 
48–72 h after the first vaccination. Migration was quantified 
by region-of-interest analysis of the individual nodes visu-
alized on the images and expressed as the relative fraction 
of 111In-labeled DC in the injection depot.
Immunological responses to KLH and prophylactic 
vaccines
Antibodies against KLH were measured in serum from vac-
cinated patients by ELISA (www.klhanalysis.com) [15]. 
Cellular responses against KLH and prophylactic vaccines 
were measured in a proliferation assay. Peripheral blood 
mononuclear cells (PBMC) (4 μg/2 × 105) were stimu-
lated with KLH, Act-HIB (4 % v/v), BCG-SSI (4 % v/v), 
or Typhim Vi (4 % v/v) in medium with 2 % human serum. 
After 3 days, cells were pulsed with 1 μCi/well tritiated 
thymidine for 8 h, and incorporation of tritiated thymidine 
was measured with a beta-counter. A proliferation index >2 
was considered positive.
Proliferative and cytokine response of bronchoalveolar 
lavage (BAL) cells
Autologous DC of patients V-A-01 and V-A-08 were 
matured for 48 h with the conventional cytokine cocktail 
(cDC), the complete prophylactic vaccine cocktail (VAC-
DC), or the separate prophylactic vaccines BCG, Typhim, 
or Act-HIB. cDC was loaded with KLH, gp100 peptides 
(10 μM gp100:280–288 + 10 μM gp100:154–162), or 
tyrosinase peptide (10 μM tyrosinase:369–377). 1 × 104 
DC were co-cultured with 5 × 104 autologous cells 
obtained from a bronchoalveolar lavage in RPMI + 7 % 
human serum. Cytokine production was measured in the 
supernatant after 24 h by cytometric bead array (human 
Th1/Th2 11 plex kit, eBioscience) or standard sandwich 
ELISA (human IL-17 DuoSet ELISA, R&D Systems). To 
study T cell proliferation, cells were pulsed after 4 days 
with 1 μCi/well tritiated thymidine for 8 h, and incor-
poration of tritiated thymidine was measured with a 
beta-counter.
MHC tetramer staining
SKIL and PBMC were stained with tetrameric MHC com-
plexes containing HLA-A*02:01 epitopes gp100:154–162, 
gp100:280–288, or tyrosinase:369–377 (Sanquin). HIV 
tetramers were used as a negative control.
Skin‑test infiltrating‑lymphocytes cultures
One to two weeks after the last DC vaccination, a DTH skin 
test was performed, as described (https://www.labtube.tv/
video/Skin-test-infiltrating-lymphocyte-SKIL-test-120284) 
[16, 17]. For HLA-A*02:01-positive patients, antigen 
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recognition was determined by the production of cytokines 
of SKIL after co-culture with T2 cells pulsed with the indi-
cated peptides or BLM (a melanoma cell line expressing 
HLA-A*02:01 but no endogenous expression of gp100 and 
tyrosinase), transfected with control antigen G250, gp100 
or tyrosinase, or an allogeneic HLA-A*02:01-, gp100-, and 
tyrosinase-positive tumor cell line (MEL624). Cytokine 
production was measured in supernatants after 24 h of co-
culture with a FlowCytomix Multiplex kit (Bender MedSys-
tems GmbH). For HLA-A*02:01-negative patients, antigen 
recognition by SKIL was determined using autologous 
EBV-transformed B (EBV-B) cells electroporated with 
gp100-mRNA or tyrosinase mRNA as described [18, 19].
Statistical analysis
Planned patient accrual was 25 in protocol A and 17 in 
protocol B. Data were analyzed statistically by means of 
analysis of variance and Student–Newman–Keuls test, or 
by means of Mann–Whitney U nonparametric statistics. 
Statistical significance was defined as p < 0.05. Progres-
sion-free and overall survival were calculated from the time 
from apheresis to disease recurrence (for stage III patients) 
or progression (for stage IV patients) or death. Differences 
between Kaplan–Meier estimates of survival times were 
assessed using the log-rank test.
Results
Patient characteristics and vaccination cycles
A total of 29 melanoma patients, 11 stage III patients and 
18 stage IV patients, were included. One stage IV mela-
noma patient showed rapid progressive disease with signs 
of spinal cord compression before vaccination started and 
went off study to receive local treatment. Sixteen patients 
were vaccinated i.v./i.d (protocol A); 12 patients were vac-
cinated i.n. (protocol B; Supplementary Figure 1). Patient 
characteristics are summarized in Table 1.
In the i.v./i.d. group, the first five patients received 
increasing doses of VAC-DC (7.5 to 30 × 106 DC). Eight 
additional patients received the full dose of maximally 
30 × 106 VAC-DC. Due to serious side effects (see below), 
the maximum dose was reduced to 15 × 106 DC. As toxic-
ity did not diminish after dose reduction, the inclusion of 
patients in protocol A was terminated. In the i.n. group, 
the first five patients received increasing doses of VAC-DC 
(1.5–15 × 106 DC). An additional seven patients received 
the maximum dose of 15 × 106 VAC-DC. Due to serious 
side effects (see below), none of the patients in the i.n. 
group received maintenance cycles, and further inclusion of 
patients was stopped.
Characteristics of injected DC
After maturation, VAC-DC of all patients had a mature 
phenotype based on expression of MHC class I and II, co-
stimulatory molecules, CD83, and CCR7 (Supplementary 
Figure 3a). Intracellular expression of tumor-associated 
antigens gp100 and tyrosinase after electroporation was 
variable, but for each patient expression of either gp100 or 
tyrosinase was at least 30 % (Supplementary Figure 3b).
Migratory capacity of VAC‑DC
In four patients the distribution of 111Indium-labeled VAC-
DC was determined by scintigraphic imaging 10 min and 
2–3 days after the first i.d. vaccination. In all four patients, 
VAC-DC migrated from the injection depot to multiple 
nearby lymph nodes (Fig. 1a). The median overall redistri-
bution of injected DC was 1.8 % (range 1.1–3.6 %), and 
median 3 lymph nodes were reached (range 2–4; Fig. 1b). 
These results demonstrate that VAC-DC have the capacity 
to migrate towards lymph nodes after i.d. injection.
Flu‑like symptoms and injection site reactions
Almost all patients vaccinated with VAC-DC experienced 
CTC grade 2 toxicity with higher fever and stronger injec-
tion site reaction as compared to patients vaccinated with 
cytokine-matured DC (cDC) in previous studies (Table 2, 
Supplementary Figure 4a). Interestingly, two patients in the 
i.v./i.d. group (A-2 and A-3) showed re-appearance of indu-
ration of the injection site of recent i.d. VAC-DC vaccina-
tion after regular seasonal flu vaccination (Supplementary 
Figure 4b), whereas the flu vaccine was not part of the mat-
uration cocktail. In the i.n. group, the injection site reac-
tions induced substantial lymphadenopathy and erythema 
of the overlying skin. In some cases it was accompanied by 
purulent discharge, resembling suppurative lymphadenitis 
(Supplementary Figure 4c+d).
Remarkably, patient A-3 showed vitiligo on the chest 
and back after the second cycle of i.v./i.d. VAC-DC vacci-
nations. The occurrence of vitiligo in patients with mela-
noma is reported for patients undergoing immunotherapy 
and can be an indication of an immune response directed 
against melanoma/pigmented cells and correlate with sur-
vival [20, 21].
Hepatotoxicity and pneumonitis
In all but four patients hepatotoxicity was observed. A rise 
in liver enzymes was most pronounced after i.v./i.d. injec-
tion and occurred in five patients up to CTC grade 3 sever-
ity (Table 2). Although in some patients progressive liver 
metastases could not be excluded as a causative factor, the 
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Table 1  Patient characteristics
Patient Sex Age N or M 
stagea
Baseline 
LDH
Site of 
disease
Number of 
metastasis
Gp100b Tyrosi-
naseb
HLA-
A*02:01 
status
Mutation 
status
Post-DC 
treatment
F/M Yrs U/l Intensity Intensity
i.v./i.d. ULN < 450
Stage IV A-1 F 50 M1c 663 Liver, lung, 
skin
>10 + − + wt S
A-2 F 66 M1a 383 Distant LN >5 +++ +++ + wt −
A-3 M 60 M1b 396 Distant LN, 
lung
>5 pos − + wt S, C, I
A-4 M 65 M1b 368 Lung 4 +++ − + wt C
A-5 M 32 M1c 329 Liver, 
distant 
LN, soft 
tissue
>5 pos n.t. + n.t. S
A-6 M 37 M1c 389 Liver, lung, 
bone, 
skin, 
cardiac
>10 +++ +++ + n.t. −
A-7 M 53 M1c 517 Liver, bone >5 + − + n.t. I
A-8 M 55 N3irr 445 Ingui-
nal + par-
aaortic 
LN
>5 +++ + + n.t. −
A-9 F 35 M1a 269 Skin 2 +++ +++ + BRAF S
Stage III A-10 M 46 N2b 340 Cervical 
LN
2 +++ +++ + BRAF S, T1, I
A-11 F 51 N1b 431 Inguinal 
LN
1 +++ ++ + n.t. n.a.
A-12 M 60 N1b 372 Axillary 
LN
1 +++ + − n.t. n.a.
A-13 M 64 N3 287 Cervical 
LN
5 ++ ++ − NRAS T2
A-14 F 43 N3 385 Cervical 
LN
>5 +++ +++ + BRAF −
A-15 M 51 N3 421 Inguinal 
LN
>10 ++ ++ + n.t. S
A-16 M 53 N2b 337 Inguinal 
LN
2 +++ +++ + NRAS −
i.n.
Stage IV B-1 M 60 M1b 427 Distant LN, 
lung, skin
>5 +++ +++ + BRAF S, I, T1
B-2 M 48 M1b 321 Lung, skin 5 ++ − − n.t. I
B-3 M 42 M1a 450 Distant LN, 
skin
>10 +++ +++ + wt I, S
B-4 M 69 M1b 381 Distant LN, 
lung
>5 ++ ++ + BRAF C, T1
B-5 M 57 M1c 251 Bone 1 +++ ++ − n.t. C
B-6 M 29 N3 irr 341 Axillary 
LN + in 
transit 
mets
>10 +++ + − NRAS C, I, T2
B-7 M 63 M1b 340 Lung 2 ++ ++ − wt S, I
B-8 F 56 M1a 267 Distant LN, 
skin
5 +++ +++ − BRAF −
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transient increase of liver tests during the vaccination cycle 
in most patients clearly support a toxic effect of VAC-DC 
vaccination. The increases in liver tests returned to baseline 
within 1 month after vaccination and were not accompa-
nied by alterations in bilirubin.
Six patients in the i.v./i.d. group presented with acute 
onset of dyspnea and dry cough. In the first two patients 
a CT-angiography scan was made of which the results 
excluded a pulmonary embolism. High-resolution CT scans 
of these patients and two others showed diffuse increased 
density of the lung parenchyma, classified as interstitial 
pneumonitis (Fig. 2a). All four patients were treated with a 
short course of systemic steroids, resulting in improvement 
in dyspnea within 2 days. The CT abnormalities resolved in 
one to 3 months (Fig. 2b). Two other patients presented with 
similar symptoms but did not show signs of pneumonitis on 
a planned CT scan for response evaluation. A high-resolu-
tion CT scan was not performed in these patients. A planned 
CT scan showed a segmental pulmonary embolism in one 
patient, which was considered to be a coincidental finding 
as this patient had no pulmonary complaints at that time.
Immune cells obtained from a BAL of patients A-9 and 
A-10 proliferated and produced interferon gamma (IFNγ) 
and TNFα when co-cultured with autologous VAC-DC or 
BCG alone. BAL-derived immune cells of patient A-9 also 
responded to KLH, but did not proliferate upon stimula-
tion with gp100 or tyrosinase peptides. In addition, staining 
with tetrameric MHC complexes could not demonstrate the 
presence of tumor antigen-specific T cells in the BAL fluid. 
These data suggest that at least part of the infiltrated cells 
were BCG-specific (Fig. 2c–f).
KLH‑ and BCG‑specific immune responses
To test the capacity of the patients in this study to gen-
erate an immune response, we loaded the VAC-DC with 
the control antigen KLH. All 16 evaluable patients in the 
Fig. 1  VAC-DC migration after intradermal injection. In four 
patients VAC-DC migration to nearby lymph nodes (LN) was ana-
lyzed by scintigraphy of the lymph node region 48–72 h after intra-
dermal injection of 111Indium-labeled VAC-DC. a Example of a 
scintigraphic image showing the redistribution to multiple lymph 
nodes of 111Indium-labeled DC from the injection depot (arrow) to 
four nearby LN (arrow heads) in patient A-13. b Percentage of cells 
migrated to nearby LN (left) and number of reached LN (right). One 
symbol represents a single patient who received maximally 10 × 106 
cells by intradermal injection; horizontal lines represent the median
Patient Sex Age N or M 
stagea
Baseline 
LDH
Site of 
disease
Number of 
metastasis
Gp100b Tyrosi-
naseb
HLA-
A*02:01 
status
Mutation 
status
Post-DC 
treatment
F/M Yrs U/l Intensity Intensity
Stage III B-9 F 57 N3 312 Inguinal 
LN
>5 +++ ++ + wt −
B-10 M 72 N3 353 Cervical 
LN
>5 +++ ++ − n.t. n.a.
B-11 M 37 N3 296 Inguinal 
LN
4 +++ +++ − BRAF T1
B-12 M 26 N2a 353 Axillary 
LN
2 +++ +++ − n.t. n.a.
Table 1  continued
BRAF BRAF mutation present, C chemotherapy, I immunotherapy (anti-CTLA-4), S surgery, n.a. not applicable, NRAS NRAS mutation present, 
n.t. not tested, T1 targeted therapy (BRAF inhibitor), T2 targeted therapy (MEK inhibitor), wt wild type (no BRAF or NRAS mutation present)
a As per pathology report of the radical lymph node dissection in stage III melanoma patients and per CT scan in stage IV melanoma patients
b gp100 and tyrosinase expression on the primary tumor was analyzed by immunohistochemistry. Intensity of positive cells was scored centrally 
and semi-quantitatively by a pathologist. Intensity was scored as low (+), intermediate (++), or high (+++), or not scored (pos)
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i.v./i.d. group and 11 out of 12 patients in the i.n. group 
showed increased T cell proliferation upon stimulation 
with KLH, irrespective of the dose of DC administered 
(Fig. 3a). The only patient who did not show an increased 
T cell response after i.n. vaccination with VAC-DC 
already had a T cell response and KLH-specific antibodies 
Fig. 2  VAC-DC-induced lung toxicity. Example of high-resolution 
CT scan (patient A-10) showing diffuse infiltration in the lungs sug-
gestive of pneumonitis (a), which resolved after short treatment with 
systemic steroids (b). Cells obtained from bronchoalveolar lavage of 
patients A-9 (c, d) and A-10 (e, f) were co-cultured with autologous 
DC loaded with KLH, gp100, tyrosinase, the prophylactic vaccine 
cocktail, or with BCG, Typhim, or Act-HIB. c, e T cell proliferation 
was measured in triplicate by incorporation of tritiated thymidine 
after 4 days. d, f Cytokine production was measured in the superna-
tant after 24 h by cytometric bead array and ELISA. In f, cytokine 
production is normalized to the highest value, due to large differences 
in concentration between the different cytokines. Maximum cytokine 
concentrations (100 %) were: IFNγ 9.7 ng/ml; TNFα 328 ng/ml; 
IL-10 161 ng/ml; IL-17 181 pg/ml. In conclusion, cells obtained from 
the bronchoalveolar lavage of both patients showed that infiltrated 
cells were BCG specific; this might have caused the development of 
pneumonitis
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in serum before vaccination. Overall, these data demon-
strate that both i.v./i.d. injected VAC-DC and i.n. injected 
VAC-DC effectively induced de novo immune responses 
in melanoma patients.
For some patients, we also analyzed the induction of T 
cells specific for the prophylactic vaccines that were used 
for VAC-DC maturation. As expected, prophylactic vac-
cine-specific T cell responses were already present before 
VAC-DC vaccination in some patients (Fig. 3b). How-
ever, for all three prophylactic vaccines, increased T cell 
responses were found in a part of the patients, indicating 
that the prophylactic vaccines that are used for VAC-DC 
maturation are processed by the DC and presented to spe-
cific T cells after injection.
Tumor antigen‑specific T cell responses
To study tumor antigen-specific T cell responses, DTH 
skin tests were performed. Induration of sites injected with 
VAC-DC was significantly stronger than at sites injected 
with cDC (Fig. 4a).
To investigate whether tumor-associated antigen 
(TAA)-specific immune responses were induced by 
vaccination with VAC-DC, PBMC and SKIL of HLA-
A*02:01-positive patients were screened with tetrameric 
MHC complexes. After i.v./i.d. vaccination, tetramer-
positive PBMC were detected in peripheral blood of three 
out of nine stage IV patients and two out of five stage III 
patients tested. Tetramer-positive SKIL were detected 
in two out of eight stage IV patients tested and four out 
of five stage III patients tested (Table 2). In none of the 
i.v./i.d. vaccinated stage IV patients, SKIL produced 
cytokines upon co-culture with peptide- or protein-loaded 
target cells, whereas in three stage III patients SKIL rec-
ognized endogenously processed tumor proteins. After 
i.n. vaccination, tetramer-positive CD8+ T cells were 
detected in peripheral blood of two out of three stage IV 
patients, whereas tetramer-positive SKIL were detected 
in two out of four HLA-A*02:01-positive patients, one 
stage IV, and one stage III patient. Interestingly, SKIL of 
patient B-9 produced IFNγ upon co-culture with tumor 
protein and not with HLA-A*02:01-binding peptides 
(Fig. 4b, c), indicating that T cells recognized different 
epitopes.
In one HLA-A*02:01-negative stage III patients (patient 
B-11), SKIL produced IFNγ upon co-culture with EBV-B 
cells, but without concomitant upregulation of CD69 or 
CD107a. Nevertheless, our analysis for HLA-A*02:01 pre-
sented epitopes demonstrate that VAC-DC can induce or 
enhance tumor-specific immune responses in melanoma 
patients both after i.v./i.d. and i.n. injection.
Clinical outcome in stage III patients
The median follow-up was 46 months (range 7–64). In the 
i.v./i.d. group, five patients had recurrence of disease, of 
whom three patients died and two patients are alive with 
disease. In the i.n. group, two patients had recurrence of 
disease and died. In both groups, two patients have no evi-
dence of disease (Table 2).
Fig. 3  KLH- and prophylactic vaccine-specific T cell responses 
before and after VAC-DC vaccination. a KLH-specific T cell pro-
liferation was analyzed before the first vaccination and after each 
VAC-DC vaccination during the first vaccination cycle in PBMC. 
Per time point each dots represents one patient; black dots represent 
patients that received i.v./i.d. VAC-DC vaccination, open dots repre-
sent patients that received i.n. VAC-DC vaccination. Horizontal lines 
represent group averages per time point. In all patients except one, a 
KLH-specific T cell response was induced. b BCG-, Act-HIB-, and 
Typhim-specific T cell proliferation was analyzed before and after 
VAC-DC vaccination in PBMC. Proliferative responses to KLH or 
prophylactic vaccines are given as proliferation index (prolifera-
tion with KLH or vaccines/proliferation without KLH or vaccines). 
**p < 0.01, paired t test
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Clinical outcome in stage IV patients
The median follow-up was 12 months (range 3–54). All 
stage IV patients were evaluated for clinical response at 
3-month intervals with CT scans or at earlier time points 
when progressive disease was clinically suspected. In the 
i.v./i.d. group, one patient had stable disease and received 
a second vaccination cycle. The remaining eight patients 
showed progressive disease prior to or at first evaluation. 
Patient A-9 is still alive with follow-up of nearly 4 years 
(April 2015), and the other eight patients died between 3 
and 21 months. Mutation status and subsequent treatments 
after progressive disease are shown in Table 1.
In the i.n. group, three patients had stable disease 
(8–14 months), of which one had a mixed response, show-
ing a reduction in size of mediastinal lymph node metasta-
sis and a increase in size of abdominal lymph node metas-
tasis. The other five patients showed progressive disease at 
the first clinical evaluation. All patients died between 8 and 
36 months (Table 2).
Despite the small sample size, our data suggest a cor-
relation between the immunological responses and survival 
Fig. 4  Tumor antigen-specific T cell responses in skin-test infil-
trating-lymphocyte cultures. a Induration of delayed-type hyper-
sensitivity (DTH) sites measured 48 h after intradermal injection of 
VAC-DC or cytokine-matured DC (cDC) loaded with gp100 mRNA 
or tyrosinase mRNA. Data are shown in mm induration. Each dot 
represents one DTH site. The line indicates the mean of DTH sites. 
*** p < 0.001, ns not significant, paired t test. b Example of tetramer 
staining of T cells cultured from a DTH site of patient B-9. Cells 
were stained with allophycocyanin-labeled tetramers encompass-
ing the gp100:154 peptide, gp100:280 peptide, tyrosinase peptide, or 
control peptide and with CD8-FITC. Numbers indicate the percentage 
of tetramer-positive cells CD8+ T cells of total CD8+ T cells. c IFNγ 
production by the same T cells of patient B-9 after stimulation with 
T2 cells loaded with tumor peptides or BLM cells expressing tumor 
proteins. d Kaplan–Meier analyses of overall survival according to 
the presence of tetramer-positive populations in skin-test infiltrating-
lymphocyte cultures from DTH skin-test biopsies or in peripheral 
blood in HLA-A*02:01-positive stage IV patients. The presence of 
tumor antigen-specific T cells (Tc+) correlates with longer overall 
survival after VAC-DC vaccination in metastatic melanoma patients 
compared to patients without detectable tumor antigen-specific T 
cells (Tc-)
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of HLA-A*02:01-positive patients, with an overall survival 
ranging from 14 to 28 months in patients with TAA-spe-
cific T cells (n = 4), whereas in the absence of these cells 
(n = 7) the overall survival ranges from 3 to 11 months 
(p = 0.003; Fig. 4d).
Discussion
Based on our in vitro data, showing the potential of DC 
matured by a cocktail of three prophylactic vaccines (BCG, 
Typhim, and Influvac or Act-HIB) and PGE2 [11], we 
initiated a study on the safety and the capacity to induce 
immune responses against tumor antigens of VAC-DC 
in vivo. Our major conclusions are (1) VAC-DC can induce 
tumor antigen-specific T cell responses, both after i.v./i.d. 
and i.n. injection; (2) VAC-DC induce more severe side 
effects as compared to cDC matured with a conventional 
cytokine cocktail.
Side effects of cDC vaccines are usually mild and if pre-
sent include low-grade flu-like symptoms and local reaction 
at the injection site. Compared with our experience with 
cDC vaccination [4, 13, 22, 23] and the experience of other 
groups with Trimix-matured or α type 1-polarized moDC 
[7, 24, 25], in the present study with VAC-DC vaccination 
side effects were of higher grade and occurred more often 
as well as earlier after the first vaccination. Injection site 
reactions are uncommon upon i.n. injection with cDC [26]; 
however, upon VAC-DC vaccination substantial lymphad-
enopathy and erythema of the overlying skin were observed 
with purulent discharge occurring in some patients. In addi-
tion, flu-like symptoms were more severe after VAC-DC 
vaccination compared to cDC vaccination and were more 
often accompanied by the presence of fever. Both the injec-
tion site reactions and flu-like symptoms were self-limiting 
but dissolved less rapidly. The foreign KLH antigen in cDC 
vaccines is regarded a major cause of fever and flu-like 
symptoms after vaccination with cDC. However, in VAC-
DC the BCG vaccine may be responsible for both the side 
effects, since prophylactic BCG vaccination, intravesicu-
lar BCG treatment in bladder cancer patients, and active 
specific immunotherapy with BCG in colon carcinoma 
patients are known to induce flu-like symptoms, fever and 
suppurative lymphadenitis, resembling the clinical picture 
we observed, as well as pulmonary infiltrates and increased 
liver function tests [27–29]. The relation between the pneu-
monitis and the usage of the BCG vaccine in the matura-
tion cocktail of the VAC-DC was substantiated by the 
observed proliferation and cytokines production in immune 
cells obtained from BAL in response to stimulation with 
BCG antigens. We hypothesize that VAC-DC trapped in 
the lungs after i.v. injection attract BCG-specific immune 
cells, thereby causing pneumonitis. Symptoms started in 
the second cycle of vaccinations in three patients and in 
the first cycle (after the second vaccination) in one patient 
with a proven pneumonitis. This suggests that the BCG-
specific cells were induced by the first round of VAC-DC 
vaccinations. The patient who developed pneumonitis after 
the second vaccination had a very high BCG-specific T 
cell proliferation index before vaccination, suggesting that 
these cells were already present prior to VAC-DC vaccina-
tion. Attempts to replace or remove BCG from the matura-
tion cocktail consisting of prophylactic vaccines have so far 
been unsuccessful, as BCG appears to be essential to obtain 
IL-12-producing DC with a mature phenotype [11]. Both 
protocols were prematurely terminated; this was mainly 
due to the pulmonary toxicity (protocol A) that occurred 
and the extensive injection site reactions (protocol B).
For DC to induce an effective immune response, it is 
crucial to migrate to the T cell areas of the lymph node 
after injection. VAC-DC express CCR7, and our in vivo 
data show that after i.d. injection VAC-DC migrate towards 
regional lymph nodes. Compared to our previous migration 
studies with i.d. injected cDC [30], i.d. injected VAC-DC 
migrate in a comparable percentage to nearby lymph nodes 
but to a somewhat larger number of nodes. Our in vitro 
studies showed that addition of PGE2 to the vaccine cock-
tail is needed to obtain DC that are responsive to lymph 
node chemokines [11]. However, PGE2 also has suppres-
sive activities, including suppression of IL-12 production 
by DC [31]. Indeed, in our in vitro studies, addition of 
PGE2 to the maturation cocktail reduced IL-12 production. 
However, secreted IL-12 levels were still 100-fold higher 
than levels secreted by cytokine-matured DC and sufficient 
to induce IFNγ-producing Th1 cells [11].
Vaccination with VAC-DC induced tumor antigen-
specific CD8+ T cell responses, both after i.v./i.d. injec-
tion and after i.n. injection. Previously, we showed that 
the presence of tumor antigen-specific T cells in DTH skin 
tests positively correlates with clinical outcome in meta-
static melanoma patients after cDC vaccination [16, 17]. 
Although groups are too small to draw firm conclusions, 
we found a similar correlation between the immunological 
responses and overall survival in stage IV HLA-A*02:01-
positive melanoma patients. In line with our previous stud-
ies [13, 16, 32], robust immunologic responses were more 
frequently detected in patients with no evidence of disease 
(stage III melanoma) than in patients with macroscopic 
tumor burden (stage IV). This is in line with the hypoth-
esis that high tumor burden may hamper the induction of 
effective immune responses by the secretion of suppressive 
cytokines and attraction of regulatory T cells [33].
In the i.v./i.d. group the percentage of patients with 
immunological responses was comparable to that after 
vaccination with cDC [16]. By contrast, in the i.n. group 
very few tumor antigen-specific immune responses were 
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detected. The majority of patients in this group were HLA-
A*02:01 negative, which is, however, not a prognostic fac-
tor in melanoma but might be predictive for response to DC 
vaccination [34]. In theory, as DC were loaded with mRNA 
encoding the whole TAA, this obviates HLA restriction 
and allows immune responses against a broad array of 
epitopes. Unfortunately, the monitoring of tumor antigen-
specific immunological responses in HLA-A*02:01-neg-
ative patients is far more complicated, and the alternative 
approach using EBV-B cells might not allow the detec-
tion of all tumor antigen-specific immune responses [18]. 
Furthermore, the low frequency of tumor antigen-specific 
immune responses may be due to the i.n. injection route 
[35], which may cause partial destruction of the lymph 
node architecture. Additionally, after i.d. injection, the DC 
that reach the lymph nodes may represent the most mature 
and hence most potent DC. Lastly, patients in the i.n. group 
received lower number of vaccinations, due to treatment 
discontinuation for reasons of toxicity.
We conclude that vaccination of melanoma patients 
with VAC-DC results in functional tumor antigen-specific 
T cell responses, however, at the cost of substantial toxic-
ity. This impedes the general application of VAC-DC, as 
DC-based immunotherapy nowadays competes with the 
immune checkpoint inhibitors, and its main advantages are 
the limited toxicity and maintenance of good quality of life. 
To avoid this toxicity but still allow the benefit from VAC-
DC-induced immunological responses, GMP-grade puri-
fied TLR ligands may be an alternative.
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